Galapagos and OneWorld Health Announces Collaboration

Galapagos NV has announced that its service division BioFocus DPI has entered into a drug discovery collaboration with the Institute for OneWorld Health.

OneWorld Health is working on a number of drug development initiatives for neglected diseases, with support from the Bill & Melinda Gates Foundation and other donors. 

The collaboration focuses on the development of drugs to combat diarrheal diseases. 

Under the terms of the agreement, BioFocus DPI will apply its medicinal chemistry expertise to identify drug candidates for OneWorld Health’s diarrheal disease program. 

Total contract value for Galapagos exceeds €3 million over two and a half years.
 
Under the scope of the project, BioFocus DPI will offer its expertise in medicinal chemistry to identify potential drug candidates for future development.
 
"We are very proud that OneWorld Health has chosen to award this project of major health concern to BioFocus DPI," said Onno van de Stolpe, CEO of Galapagos. 

"This collaboration further illustrates BioFocus DPI’s ability to apply its versatile drug discovery approach to a wide range of disease areas."

"We are pleased to be able to contribute to the worldwide research effort aimed at saving lives of children in developing world countries."
 
"BioFocus DPI’s expertise in generating new drug leads will contribute to the advancement of our drug development program in diarrheal diseases," said Dr. Victoria Hale, Founder and CEO of OneWorld Health. 

"Their medicinal chemistry knowledge and high standards of research will help us to reach our goal of developing safe, effective and affordable drugs for the treatment of diarrheal diseases in developing countries."